Live Breaking News & Updates on Cytokinetics incorporated

Stay informed with the latest breaking news from Cytokinetics incorporated on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Cytokinetics incorporated and stay connected to the pulse of your community

Cytokinetics Appoints Sung H. Lee as New CFO

has shared an update. Sung H. Lee is set to join Cytokinetics, Incorporated as the Executive Vice President and Chief Financial...

Cytokinetics-incorporated , Executive-vice-president , Chief-financial , News , Ggregator , Reaking-news , Uration , Edia ,

Cytokinetics to Announce First Quarter Results on May 8, 2024

Cytokinetics to Announce First Quarter Results on May 8, 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cytokinetics-diane-weisersenior , Youtube , Exchange-commission , Facebook , Cytokinetics-incorporated , Cytokinetics-incorporated-nasdaq , Linkedin , Corporate-affairs , Private-securities-litigation-reform-act , Safe-harbor , Cytokinetics-diane-weisersenior-vice-president ,

Cytokinetics to Announce First Quarter Results on May 8, 2024

Cytokinetics to Announce First Quarter Results on May 8, 2024
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Cytokinetics-incorporated ,

Needham & Company LLC Reaffirms Buy Rating for Cytokinetics (NASDAQ:CYTK)

Needham & Company LLC reissued their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $108.00 price objective on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. Oppenheimer reiterated an outperform rating and […]

Los-angeles , California , United-states , Fady-ibraham-malik , Roberti-blum , Raymond-james , Nasdaq , Cytokinetics-company-profile , Needham-company , Cytokinetics-incorporated , Vanguard-group-inc , Fisher-asset-management

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Lisbon , Lisboa , Portugal , Scotland , Martin-maron , Cytokinetics-diane-weisersenior , Mary-ellen-jay , Gregory-lewis , Scotland-inherited-cardiac-conditions-service , Cytokinetics-incorporated , Linkedin

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024…

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024…
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Cytokinetics-incorporated , Primary-results , Positive-topline-results , Obstructive-hypertrophic , Additional-analyses , Exercise-capacity , Late-breaking ,

Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fifteen analysts that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month […]

Maryland , United-states , America , Fady-ibraham-malik , Raymond-james , Johnt-henderson , Securities-exchange-commission , Quadrant-capital-group , Morgan-stanley , Cytokinetics-incorporated , Financial-services-group-inc , Mutual-of-america-capital-management

HC Advisors LLC Invests $271,000 in Cytokinetics, Incorporated (NASDAQ:CYTK)

HC Advisors LLC acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,243 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. Other institutional investors and hedge […]

China , Fady-ibraham-malik , Roberti-blum , Chilton-capital-management , Morgan-stanley , Hc-advisors , Cytokinetics-incorporated , Needham-company , Cytokinetics-company-profile , Exchange-commission , China-universal-asset-management-co , Securities-exchange-commission

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology…

SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated CYTK today announced additional 48-week data from FOREST-HCM…

United-states , American , Cytokinetics-incorporated , Research-evaluation-of-sustained-treatment , Research-evaluation , Sustained-treatment , Annual-american , News , Ggregator , Reaking-news , Uration

Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session

Cytokinetics, Incorporated announced additional 48-week data from FOREST-HCM , the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy , at the 73rd Annual...

Research-evaluation-of-sustained-treatment , York-heart-association , American-college-of-cardiology , Cytokinetics-incorporated , Research-evaluation , Sustained-treatment , Annual-american-college , Scientific-session , New-york-heart-association , Functional-class , Markets